Skip to content


BMC Proceedings

Open Access

Molecular characterization of extended-spectrum-β-lactamases producing Klebsiella pneumoniae and Escherichia coli from hospitalized patients in Oman

  • Lobna Mourad1, 2,
  • Matilda Nicklasson2,
  • Rania Siam1 and
  • Guillermo Pimentel2
BMC Proceedings20093(Suppl 3):O10

Published: 1 July 2009


Escherichia ColiNosocomial InfectionGenotypic VariationAntimicrobial ResistanceKlebsiella Pneumoniae

Extended-spectrum β-lactamases (ESBLs) are plasmid encoded enzymes that confer resistance to β-lactam antibiotics through the hydrolysis of the β-lactam ring. ESBLs are distributed worldwide with an increasing incidence and prevalence in the Middle East due to the misuse of antibiotics and lack of coherent antimicrobial surveillance studies. The aim of study is to analyze molecularly the antimicrobial resistance mechanisms of 50 Escherichia coli and Klebsiella pneumoniae isolates from nosocomial infections in hospitalized patients in Oman. Screening for antimicrobial resistance (AR) and ESBL production was carried out with the disk diffusion and E-test methods following CLSI guidelines. ESBL producers were screened for blaCTX-M, blaSHV, and blaTEM resistance markers via PCR using gene-specific primers. All amplified PCR fragments will be sequenced to determine their allelic variants. In order to demonstrate the overall genotypic variation, Pulsed-Field Gel Electrophoresis (PFGE) analyses were done separately among all E. coli and K. pneumoniae isolates. According to the AR analysis, 82% (41/50) of isolates were determined to be ESBL producing bacteria. The percentages of isolates with genetic markers for blaCTX-M, blaSHV, and blaTEM were 73%, 24%, and 68%, respectively. Preliminary PFGE analyses demonstrated high level of variation among ESBL isolates compared to non-ESBL producers. Further surveillance studies are needed to describe better the AR situation in these hospitals in Oman.

Authors’ Affiliations

Biotechnology Graduate Program, American University in Cairo, Egypt
US-Naval Medical Research Unit-3, Cairo, Egypt


© Mourad et al; licensee BioMed Central Ltd. 2009

This article is published under license to BioMed Central Ltd.